32nd Annual Symposium on the Etiology, Pathogenesis, and Treatment of Parkinson Disease and Other Movement Disorders

Presented by the Parkinson Study Group in collaboration with the Huntington Study Group, Dystonia Study Group, Cooperative Ataxia Group and Tremor Research Group

Saturday, April 6, 2019
Sheraton Grand at Wild Horse Pass, Phoenix, AZ
8:00 a.m. – 1:30 p.m.

Theme: Advancing Clinical Trials in PD and Neurodegenerative Disorders:

8:00-8:10 Intro/Acknowledgements and Presentation of Abstract Awards
Jeff Bronstein, Chair, PSG Symposium Committee

8:10-8:25 Parkinson Disease Abstract Presentation: Efficacy and Safety of Apomorphine Sublingual Film for the Treatment of “OFF” Episodes in Patients with Parkinson’s Disease: A Phase 3, Double-Blind, Placebo-Controlled Trial, Stewart Factor, DO, Emory University, Atlanta, GA (10 min/5 min Q&A)

8:25-8:40 Other Movement Disorder Abstract Presentation: Are Lewy bodies associated with sympathetic pathology in dementia subjects? David Shprecher, DO, Banner Sun Health Research Institute, Sun City, AZ (10 min/5 min Q&A)

8:40-9:35 PRESENTATION: The rationale for targeting LRRK2 and GBA
Andrew West, PhD, Professor, Duke Center for Neurodegeneration Research, Departments of Pharmacology and Cancer Biology and Neurology, Durham, NC (45 min talk/10 min Q&A)

9:35-10:30 PRESENTATION: Parkinson Phenotype of Patients with LRRK2 and GBA mutations
Susan Bressman, MD, Professor and Chair, Department of Neurology at Mount Sinai Beth Israel, New York, NY (45 min talk/10 min Q&A)

10:30-12:00 FORMAL POSTER SESSION (Poster highlights for 5 minutes)
Poster Highlight #1: Safety and Efficacy of VY-AADC01 for Medication Refractory Parkinson’s Disease in an On-going Phase 1b study, Chad Christine, MD, University of California San Francisco, San Francisco, CA

Poster Highlight #2: Preliminary findings of the use of cannabis in Parkinson disease, Maureen Leehey, MD, University of Colorado Denver, Aurora, CO

12:00-12:55 PRESENTATION: The Current Status of Clinical Trials Targeting Patients with LRRK2 and GBA mutations
Brian Fiske, PhD, Senior Vice President, Research Programs, The Michael J. Fox Foundation for Parkinson’s Research (45 min talk/10 min Q&A)

12:55-1:25 PRESENTATION: Patient Perspectives on Living with an Inherited Form of Parkinson Disease
Mr. Ofer Nemirovsky, Patient Advocate, Boston, MA (20 min talk/10 min Q&A)

1:25-1:30 Closing Remarks: Jeff Bronstein, Chair, PSG Symposium Committee